Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Butabarbital. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.71 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.71 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butabarbital SCHEMBL122122 | 1.00 | CYP3A4 (0.71) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Butabarbital SCHEMBL79254 | 1.00 | CYP3A4 (0.71) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Butabarbital SCHEMBL9862052 | 0.98 | CYP3A4 (0.69) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Butabarbital SCHEMBL122123 | 0.98 | CYP3A4 (0.69) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Butabarbital SCHEMBL8717769 | 0.96 | CYP3A4 (0.67) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL2376470 | 0.83 | CYP3A4 (1.00) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL735353 | 0.83 | CYP3A4 (1.00) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| SCHEMBL120257 | 0.83 | LMNA (0.73) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| SCHEMBL9305362 | 0.83 | CYP3A4 (0.67) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| SCHEMBL120258 | 0.83 | LMNA (0.73) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6928 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041939-A1 | METHODS FOR THE TREATMENT OF HYPERTENSION VIA TRANSCRANIAL-FOCUSED-ULTRASOUND | SUNNYBROOK RES INST (CA) | 2026-02-12 | — | — | US | claimed |
| EP-3441087-B1 | METHODS OF TREATING CHRONIC PAIN | TEVA PHARMACEUTICALS INT GMBH (CH) | 2025-02-19 | — | — | EP | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| CN-111432873-B | Treatment of type 1 diabetes | 加尔瓦尼生物电子有限公司 | 2024-08-13 | — | — | CN | claimed |
| US-20240238250-A1 | METHOD OF USING PIROMELATINE FOR TREATING PARASOMNIAS ASSOCIATED WITH LOSS OF REM SLEEP ATONIA | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2024-07-18 | — | — | US | claimed |
| WO-2024150170-A1 | PIROMELATINE FOR TREATING PARASOMNIAS ASSOCIATED WITH LOSS OF REM SLEEP ATONIA | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2024-07-18 | — | — | WO | claimed |
| WO-2023055939-A9 | APPARATUS, SYSTEMS AND METHODS FOR TRANSDERMAL DRUG DELIVERY, PERMEABILITY ENHANCEMENT AND AUGMENTATION | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2024-04-25 | — | — | WO | claimed |
| US-11858909-B2 | Deuterated etoricoxib, methods of manufacture, and use thereof | Tremeau Pharmaceuticals, Inc. (US) | 2024-01-02 | — | — | US | claimed |
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | claimed |
| US-20230355632-A1 | DEUTERATED PARAXANTHINE AND USES THEREOF | Lennham Pharmaceuticals, Inc. (US) | 2023-11-09 | — | — | US | claimed |
| EP-0900086-A4 | ENHANCEMENT OF SLEEP WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO INC (US) | 2000-01-12 | — | — | EP | claimed |
| WO-1999022244-A2 | METHOD FOR DETERMINATION OF DRUGS OF ABUSE IN BIOLOGICAL SAMPLES | VARIAN, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| EP-0900086-A1 | ENHANCEMENT OF SLEEP WITH A GROWTH HORMONE SECRETAGOGUE | Merck & Co., Inc. (US) | 1999-03-10 | — | — | EP | claimed |
| WO-1997041879-A1 | ENHANCEMENT OF SLEEP WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| US-5646131-A | Method for solubilizing drugs using cyclodextrins and carboxylic acids | THE ARAB COMPANY FOR DRUG INDUSTRIES AND MEDICAL APPLICANCES (ACDIMA) (JO) | 1997-07-08 | — | — | US | claimed |
| US-5593693-A | Effervescent mixture with alkali metal salts or lysinates of acidic, insoluble or slightly soluble active ingredients | Gergely, Gerhard (AU) | 1997-01-14 | — | — | US | claimed |
| US-4244939-A | RADIOIMMUNOASSAY | BAXTER TRAVENOL LABORATORIES, INC. (US) | 1981-01-13 | — | — | US | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |
| US-RE29875-E | THEOPHYLLINE SOLUBILIZED BY GLYCERYL GUAIACOLATE, POTASSIUM GUAIACOL SULFONATE OR GUAIACOL | MEAD JOHNSON & COMPANY (US) | 1979-01-02 | — | — | US | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |